Managing High-Cost Claims in Employer-Sponsored Health Plans
The demand for proactive management over reactive strategies in addressing high-cost claims within employer-sponsored health plans is increasing, as highlighted by QBE North America's 2026 Accident and Health Market Report. According to the report, which leverages QBE's extensive claims data, neoplasms account for 36% of stop-loss claim reimbursements. At the $200,000 deductible level, the severity of neoplasm claims surged by 12%, alongside a nearly 30% rise in frequency. Additionally, the frequency of members incurring claims over $200,000 annually per 10,000 employees escalated nearly 20% year-over-year, primarily driven by neoplasms, childbirth claims, and circulatory diseases.
The Business Group on Health's 2026 Employer Health Care Strategy Survey underscores these pressures, naming cancer as the leading healthcare cost driver for the fourth straight year. Employers anticipate a 9% median increase in healthcare costs for 2026. Pharmacy expenses, projected to rise between 11% and 12% annually through 2026, are fueled by specialty drugs and innovative therapies, with prescription drugs comprising 24% to 27% of total health plan expenditures.
Tara Krauss, President of Accident and Health at QBE North America, remarked on the rising prevalence of high-cost claims, highlighting the necessity for proactive management. The advent of prolonged hospital stays, new treatments, and specialty pharmaceuticals are notably escalating costs and altering the risk management landscape of employer-sponsored health plans.
These developments significantly impact the already strained stop-loss market. Allied Market Research valued the U.S. stop-loss market at $26.9 billion in 2024. The notable acquisition of Allstate's employer stop-loss division by Nationwide for $1.25 billion indicates consolidation and strong capital investment interest. QBE's 2025 results revealed heightened claim severity within its North America Accident and Health sector, leading to over 20% rate increases. Segal's 2025 survey indicated a 9.7% average premium escalation for unchanged coverage levels. Notably, claims exceeding $250,000, while affecting less than 1% of members, accounted for 15% of total medical and prescription costs.
According to Aegis Risk, 49% of self-funded plan sponsors report claims surpassing $1 million, a substantial increase from 23% in 2024. Major insurance carriers like Cigna, Voya, and Sun Life encountered challenging claims in late 2024 arising from advanced cancer treatments and premature births. Aegis noted that $3 million claims have become a new norm, with one in six sponsors facing them.
The increase in employers moving towards self-funded models, as reported by the KFF 2025 Employer Health Benefits Survey, has 37% of employees in companies with 10 to 199 employees participating in level-funded plans. Combined self-funded solutions currently cover 51% of employees within this market segment, escalating exposure to stop-loss risk amid rising claim volatility. Employers well-prepared with data and understanding of clinical risks before renewals can negotiate more favorable stop-loss terms.
For brokers and benefits advisors, these findings from QBE emphasize increased variability and unpredictability in claim outcomes. Specialized populations such as pediatric and transplant patients add complexity to already challenging risk profiles. Krauss emphasized the critical importance of prevention, early intervention, and proactive cost management as employers face mounting pressures from rising medical expenses and intensified claim severity.